标题：0.05% 卤倍他索乳膏治疗慢性手部湿疹的系统评价和荟萃分析方案。

Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis.

机构信息

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P. R. China.

出版信息

Medicine (Baltimore). 2021 Mar 12;100(10):e24418. doi: 10.1097/MD.0000000000024418.

DOI:10.1097/MD.0000000000024418

PMID:33725820

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7969293/

Abstract

BACKGROUND

Chronic hand eczema (CHE) is a recurrent, frequently disabling skin condition that requires daily skin care to prevent transepidermal water loss, posing a significant burden of society and economy. In recent years, topical 0.05% clobetasol cream is widely used for the treatment of CHE for its efficacy, tolerability and safety. Whereas, no systematic review and meta-analysis has been updated up to now. Therefore, this work aims to assess the effectiveness and safety of topical 0.05% clobetasol cream in patients with CHE.

METHODS

Study on topical 0.05% clobetasol cream for CHE will be searched from their inception to December, 2020 with the language restrictions of English and Chinese in 8 databases (PubMed, Cochrane Library, Embase, the web of science, VIP, CNKI, CBM, and WAN FANG). According to the heterogeneity test, a fixed or random-effect model will be used to synthesize data. The primary outcome is the proportion of patients achieving more than 75% reduction in signs and symptoms according to the Hand Eczema Severity Index (HECSI). The secondary outcomes include: scored for 4 different characteristics of the lesions (redness, scaling, lichenification, and pruritus), QoL questionnaire, adverse events, and recurrence events. STATA 13.0 and Review Manager software 5.3 will be used for analysis and synthesis. Two or more reviewers will independently conduct the selection of studies, data extraction, and data analysis.

RESULTS

The results of the study expect to provide a high-quality, evidence-based recommendation on topical 0.05% clobetasol cream in the treatment of CHE for clinicians.

CONCLUSION

The study will provide scientific and useful evidence for better use of topical 0.05% clobetasol cream in treating CHE.

ETHICS AND DISSEMINATION

This study is a protocol for an overview of SRs/MAs that did not involve individual data. Thus, ethical approval is not required.

OSF REGISTRATION NUMBER

DOI 10.17605/OSF.IO/SPHVZ.

摘要

背景

慢性手部湿疹（CHE）是一种反复发作的、常导致残疾的皮肤病，需要日常皮肤护理以防止经表皮水分丢失，给社会和经济带来重大负担。近年来，外用 0.05%氯倍他索乳膏因其疗效、耐受性和安全性而被广泛用于治疗 CHE。然而，迄今为止，尚无系统评价和荟萃分析对此进行更新。因此，本研究旨在评估外用 0.05%氯倍他索乳膏治疗 CHE 的有效性和安全性。

方法

从建库至 2020 年 12 月，我们将用英语和中文语言限制，在 8 个数据库（PubMed、Cochrane 图书馆、Embase、Web of Science、VIP、CNKI、CBM 和万方）中检索外用 0.05%氯倍他索乳膏治疗 CHE 的研究。根据异质性检验，我们将使用固定或随机效应模型来综合数据。主要结局是根据手部湿疹严重指数（HECSI），患者在体征和症状方面改善超过 75%的比例。次要结局包括：4 种皮损特征（红斑、鳞屑、苔藓化和瘙痒）评分、生活质量问卷、不良事件和复发事件。我们将使用 STATA 13.0 和 Review Manager 软件 5.3 进行分析和综合。两名或更多审查员将独立进行研究选择、数据提取和数据分析。